Compare
Arcus Biosciences, Inc. vs Schrodinger, Inc. vs Anaptysbio, Inc vs Arvinas, Inc.
| Latest fiscal year | Arcus Biosciences, Inc. RCUS | Schrodinger, Inc. SDGR | Anaptysbio, Inc ANAB | Arvinas, Inc. ARVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $247.00M | $255.87M | $234.60M | $262.60M |
| Revenue growth (YoY) | -4.3% | +23.3% | +157.0% | -0.3% |
| Gross margin | n/a | 55.7% | n/a | n/a |
| Operating margin | -156.3% | -65.2% | 20.4% | -45.1% |
| Net margin | -142.9% | -40.4% | -5.6% | -30.8% |
| Net income | -$353.00M | -$103.27M | -$13.23M | -$80.80M |
| EPS (Diluted) | -$3.29 | -$1.41 | -$0.46 | -$1.14 |
| Operating cash flow | -$482.00M | $13.90M | $19.70M | -$273.80M |
| Free cash flow | -$484.00M | $12.46M | $19.61M | -$275.70M |
| Cash & equivalents | $222.00M | $230.52M | $238.20M | $142.90M |
| Total assets | $1.14B | $726.16M | $364.39M | $717.90M |
| Total liabilities | n/a | $362.11M | n/a | $284.00M |
| Shareholders' equity | $631.00M | $364.05M | $37.21M | $433.90M |
| Return on year-end equity | -55.9% | -28.4% | -35.6% | -18.6% |
| Shares outstanding | 125.30M | n/a | 28.02M | 63.50M |
Revenue, most recent five fiscal years
| Fiscal year | Arcus Biosciences, Inc. | Schrodinger, Inc. | Anaptysbio, Inc | Arvinas, Inc. |
|---|---|---|---|---|
| Latest | $247.00M Ended 2025-12-31 | $255.87M Ended 2025-12-31 | $234.60M Ended 2025-12-31 | $262.60M Ended 2025-12-31 |
| 1 year earlier | $258.00M Ended 2024-12-31 | $207.54M Ended 2024-12-31 | $91.28M Ended 2024-12-31 | $263.40M Ended 2024-12-31 |
| 2 years earlier | $117.00M Ended 2023-12-31 | $216.67M Ended 2023-12-31 | $17.16M Ended 2023-12-31 | $78.50M Ended 2023-12-31 |
| 3 years earlier | $112.00M Ended 2022-12-31 | $180.96M Ended 2022-12-31 | $10.29M Ended 2022-12-31 | $131.40M Ended 2022-12-31 |
| 4 years earlier | $383.00M Ended 2021-12-31 | $137.93M Ended 2021-12-31 | $63.17M Ended 2021-12-31 | $53.60M Ended 2021-12-31 |